Give 300 mg of immediate-release (non-enteric-coated) aspirin, chewed rather than swallowed whole, as soon as ACS is suspected and before fibrinolytic therapy begins. European Society of Cardiology guidance (2023 ACS guidelines) specifies a 150–300 mg loading dose; US and UK practice (AHA/ACC and NICE) converge on 300 mg. Enteric-coated tablets and doses at or below 75 mg are the wrong choice in this window. Hold the drug only for true allergy, active bleeding, or another documented contraindication, and give it before the fibrinolytic infusion starts, not after.
What the Guidelines Actually Specify for the Loading Dose
Three major guideline families converge on 300 mg, with one small divergence worth knowing. The European Society of Cardiology's 2023 acute coronary syndromes guideline states a loading dose of 150–300 mg of aspirin for patients not already on maintenance therapy. The American Heart Association/American College of Cardiology and the UK's NICE both land on 300 mg as the standard loading dose in suspected ACS. That 150 mg floor exists because some European protocols use lower loading doses in specific populations; it is not a signal that 150 mg is equivalent for everyone.
The number matters because aspirin's benefit in ACS is time-critical and dose-dependent at the platelet level. A 300 mg dose produces rapid, near-complete inhibition of thromboxane A2 production through irreversible acetylation of platelet cyclooxygenase-1. Platelets cannot synthesize new enzyme, so the effect lasts the platelet's lifespan of roughly 7–10 days. That irreversibility is exactly why the loading dose is given once and not repeated daily at 300 mg.
For patients already taking daily low-dose aspirin (typically 75–100 mg), the guidance changes. You do not repeat the full 300 mg load; you give 75–100 mg, or in some protocols 150–300 mg is still administered depending on local policy. The practical rule taught in most emergency and cardiology settings is to confirm the patient's home aspirin dose before deciding, because double-loading a compliant patient adds bleeding risk without added antiplatelet benefit.
Fibrinolytic therapy adds a specific timing constraint. Aspirin should be given before or alongside the fibrinolytic, not deferred until after reperfusion is confirmed. The ISIS-2 trial, published in The Lancet in 1988 and enrolling over 17,000 patients, showed that aspirin alone reduced vascular mortality comparably to streptokinase alone, and the combination was additive. That evidence base is why aspirin is bundled with fibrinolytic protocols rather than treated as optional.
Why 300 mg and Not 75 mg, 150 mg, or 500 mg
The dose-response logic in ACS is about speed of platelet inhibition, not cumulative exposure. A 75 mg dose takes days to reach steady-state platelet inhibition, which is fine for secondary prevention but far too slow for an evolving coronary occlusion. A 300 mg dose achieves near-maximal inhibition within 20–30 minutes when chewed, because chewing increases the surface area for buccal and gastric absorption. That speed is the entire point in the pre-fibrinolytic window.
Higher doses do not buy more benefit. Doses above 300 mg in the acute setting have not shown superior outcomes in the trials that shaped current guidance, and they increase gastrointestinal and bleeding risk. The CURE trial (published in the New England Journal of Medicine in 2001) established that adding clopidogrel to aspirin improves outcomes in ACS, but it did not suggest escalating aspirin beyond 300 mg. The 300 mg figure is a ceiling for loading, not a floor to exceed.
There is a real-world failure mode here that guidelines do not always spell out: patients handed an enteric-coated 81 mg tablet in triage. Enteric coating delays absorption by design, sometimes by hours, which defeats the purpose in a patient with an actively occluding coronary artery. The fix is simple and often missed — crush or chew a non-enteric 300 mg tablet, or use a dispersible formulation where available.
| Dose | Form | Onset with chewing | Role in suspected ACS |
|---|---|---|---|
| 75 mg | Any | Slow (days to steady state) | Maintenance only, not loading |
| 150 mg | Non-enteric | ~20–30 min | Lower end of ESC loading range |
| 300 mg | Non-enteric, chewed | ~20–30 min | Standard loading dose (AHA/ACC, NICE) |
| 500 mg+ | Any | No faster benefit | Not recommended; more bleeding |
The table above is the comparison most quick-reference pages skip: they state the dose but not why the alternatives fail. If your formulary only stocks 81 mg tablets, you need four of them to reach roughly 324 mg, which is clinically acceptable but worth documenting as an approximation rather than a precise 300 mg.
The Contraindication Screen Before You Hand Over the Tablet
"Unless contraindicated" is doing heavy lifting in this question, so the screen deserves its own section. Absolute contraindications to aspirin in this setting include documented aspirin or NSAID anaphylaxis, active clinically significant gastrointestinal bleeding, and known severe aspirin-exacerbated respiratory disease. A history of mild dyspepsia is not a contraindication; it is a reason to co-prescribe a proton pump inhibitor later, not to withhold a life-saving antiplatelet in the acute window.
Relative contraindications require a judgment call that should involve the treating clinician, not a protocol alone. Active peptic ulcer disease without bleeding, severe thrombocytopenia, and known bleeding diatheses sit here. So does recent intracranial hemorrhage. In these cases the risk-benefit calculus may still favor aspirin if the coronary event is large and reperfusion is planned, but that decision belongs to the responsible physician and should be documented.
The contraindication that gets overcalled is "aspirin allergy." True anaphylaxis is rare; most reported reactions are gastrointestinal intolerance or mild rash. A 2021 review in the Journal of Allergy and Clinical Immunology estimated that fewer than 1% of patients labeled aspirin-allergic have a true IgE-mediated reaction. In a patient with chest pain and ST elevation, an unverified allergy label that delays aspirin is a preventable harm. Confirm the nature of the reaction when there is time; when there is not, the default in most protocols is to give the drug and monitor.
One edge case worth naming: patients on therapeutic anticoagulation. Aspirin is generally still given in ACS because the platelet pathway is separate from the coagulation cascade, but the bleeding risk is additive and the decision should be flagged to the cardiology team. This is not a reason to withhold aspirin unilaterally at the bedside.
Timing: Before, During, or After the Fibrinolytic
Give aspirin before the fibrinolytic infusion begins, or at the same time if the line is already running. The evidence for this ordering is indirect but consistent. Fibrinolysis restores flow through a clot that is still platelet-rich, and aspirin's antiplatelet effect reduces re-occlusion during and after lysis. Deferring aspirin until after lysis leaves that window unprotected.
The practical sequence in most emergency departments and coronary care units looks like this:
1: Confirm the working diagnosis of suspected ACS and check for absolute contraindications. 2: Ask whether the patient takes daily aspirin and at what dose. 3: If aspirin-naive, give 300 mg non-enteric aspirin, chewed. 4: If already on 75–100 mg daily, give 75–100 mg (or per local protocol) rather than a repeat 300 mg load. 5: Document the dose, time, and route before fibrinolytic initiation. 6: Proceed to fibrinolytic therapy per the local protocol, with aspirin already on board.
Failure handling matters here. If the patient cannot chew (reduced consciousness, dysphagia), use a dispersible formulation or crushed tablet in water via nasogastric tube if one is in place. If the patient vomits within 30 minutes of the dose, most protocols advise a repeat dose after confirming the tablet was not retained, though local policy varies. If the patient is hypotensive and absorption is uncertain, the intravenous route for aspirin is not standard in most formularies, so document the limitation and proceed with the fibrinolytic while the oral dose is given as soon as feasible.
What the Landmark Trials Established and What They Did Not
ISIS-2 is the trial that made aspirin non-negotiable in ACS. Published in The Lancet in 1988, it randomized 17,187 patients with suspected acute myocardial infarction to aspirin 162.5 mg daily for a month, streptokinase, both, or neither. Aspirin alone reduced 5-week vascular mortality by 23%, streptokinase alone by 25%, and the combination by 42%. The dose in ISIS-2 was 162.5 mg, not 300 mg, which is why some European protocols retain a 150–300 mg range rather than a single figure.
What ISIS-2 did not establish is the optimal loading dose in the modern era of dual antiplatelet therapy and primary PCI. The trial predates routine clopidogrel, ticagrelor, and prasugrel use. Contemporary ACS care layers a P2Y12 inhibitor on top of aspirin, and the aspirin dose has stayed at 300 mg loading largely by convention and consensus rather than by a head-to-head trial against 150 mg in the fibrinolytic setting.
The CURRENT-OASIS 7 trial, published in the New England Journal of Medicine in 2010, compared high-dose versus low-dose aspirin in ACS patients undergoing PCI and found no significant difference in cardiovascular events at 30 days, with more gastrointestinal bleeding in the high-dose arm. That trial is about maintenance dosing after PCI, not the initial load, and it is frequently misread as evidence against a 300 mg load. The distinction matters: the loading dose is about speed, the maintenance dose is about durability.
A third trial worth knowing is the 2019 ISAR-REACT 5, which compared ticagrelor versus prasugrel in ACS and reinforced that the P2Y12 choice, not the aspirin dose, is where most contemporary outcome difference lies. Aspirin at 300 mg loading remains the stable background against which those trials were run.
How Fibrinolytic Era Protocols Differ From Primary PCI Pathways
The aspirin dose is the same 300 mg whether the patient goes to primary PCI or receives a fibrinolytic, but the surrounding logic differs. In primary PCI, the patient is typically in a catheterization lab within 90 minutes, and aspirin is one of several antiplatelet and anticoagulant agents given in a coordinated bundle. In fibrinolytic therapy, often delivered in a smaller hospital or pre-hospital setting, aspirin is one of the few interventions that is universally available, cheap, and proven to reduce mortality as a standalone.
That difference changes the failure modes. In a PCI pathway, a missed aspirin dose can sometimes be caught up in the lab. In a fibrinolytic pathway, there is no lab to catch it — the drug either went in before lysis or it did not. This is why pre-hospital and rural protocols tend to emphasize aspirin earlier and more explicitly than tertiary PCI protocols do.
The cost dimension is also different, and it is rarely discussed. A 300 mg aspirin tablet costs pennies in most health systems, while a fibrinolytic agent like tenecteplase runs into the hundreds or thousands of dollars per dose depending on the market. The ISIS-2 mortality reduction from aspirin alone was comparable in magnitude to streptokinase alone at a fraction of the cost, which is why aspirin is the single most cost-effective intervention in the fibrinolytic bundle.
| Setting | Aspirin dose | Timing relative to reperfusion | Key failure mode |
|---|---|---|---|
| Primary PCI | 300 mg load | Before or at start of procedure | Delayed in transfer |
| Fibrinolytic (in-hospital) | 300 mg load | Before lysis infusion | Given after lysis |
| Fibrinolytic (pre-hospital) | 300 mg load | At first medical contact | Not stocked in kit |
| Already on daily aspirin | 75–100 mg | Before lysis | Full reload given in error |
Pediatric, Pregnancy, and Other Population Adjustments
Adults get 300 mg; children do not, and this is where the "unless contraindicated" phrase needs a population qualifier. Pediatric ACS is rare and usually associated with Kawasaki disease, congenital coronary anomalies, or post-cardiac surgery settings. Dosing in that population is weight-based and guided by pediatric cardiology, typically 3–5 mg/kg for antiplatelet effect, not a flat 300 mg. Do not extrapolate the adult loading dose to a child.
Pregnancy is a genuine judgment call. Aspirin at low dose (75–100 mg) is used in pregnancy for pre-eclampsia prophylaxis and is generally considered safe. High-dose aspirin in the third trimester is associated with premature closure of the fetal ductus arteriosus and bleeding risk at delivery. In a pregnant patient with suspected ACS, the decision to give a 300 mg load should involve obstetrics and cardiology, and the balance usually still favors treating the maternal coronary event, but this is not a bedside default.
Elderly patients present the opposite problem: they are more likely to be on anticoagulants, more likely to have a history of peptic ulcer, and more likely to have renal impairment that affects salicylate clearance. Age alone is not a contraindication, and withholding aspirin from an 80-year-old with STEMI because of age is a common and harmful error. The dose remains 300 mg; the monitoring for bleeding is what changes.
Patients with known aspirin hypersensitivity who nonetheless need antiplatelet therapy represent another edge case. Desensitization protocols exist and are used in elective settings, but they are not practical in an acute STEMI. In that scenario, a P2Y12 inhibitor alone may be used under cardiology guidance, and the aspirin is omitted with the reason documented.
Common Administration Errors and How to Avoid Them
The most common error is giving enteric-coated aspirin in the acute setting. Enteric coating is designed to dissolve in the alkaline environment of the small intestine, which delays absorption by 1–2 hours in some formulations. In a patient with an occluded coronary artery, that delay is clinically meaningful. The fix is to stock non-enteric 300 mg tablets in every chest pain kit.
The second most common error is giving the full 300 mg load to a patient already on daily aspirin without checking. This happens because triage protocols often say "give aspirin 300 mg" without a branch for the already-treated patient. The consequence is added bleeding risk with no added antiplatelet benefit, since the patient's platelets are already inhibited.
A third error is documenting the aspirin as given when it was only ordered. In time-critical fibrinolytic pathways, an order that has not been administered is not the same as a dose on board. Close the loop by confirming administration before the fibrinolytic starts.
The fourth error is withholding aspirin for a vague "allergy" history without clarifying it. As noted earlier, true anaphylaxis is rare, and an unverified label can delay a life-saving drug. When there is time, ask what the reaction was; when there is not, give the drug and monitor.
What Changes When the Patient Is Already on a P2Y12 Inhibitor
Patients on chronic clopidogrel, ticagrelor, or prasugrel present a layered antiplatelet picture. Aspirin is still given at the standard loading logic — 300 mg if aspirin-naive, 75–100 mg if already on daily aspirin — because the P2Y12 agent does not cover the thromboxane pathway. The two classes are additive, and ACS protocols assume both are on board.
The nuance is bleeding risk. A patient on ticagrelor plus a fresh 300 mg aspirin load has substantial platelet inhibition, and if they are also anticoagulated, the cumulative bleeding risk is real. This does not change the aspirin decision in most cases, but it changes the monitoring intensity and should be flagged to the receiving team.
There is also a drug interaction worth knowing: high-dose aspirin can attenuate the antiplatelet effect of ticagrelor in some pharmacokinetic studies, though the clinical significance is debated. The CURRENT-OASIS 7 data did not show a clear outcome penalty, and current guidance does not recommend reducing the aspirin load because of ticagrelor co-administration. Document the combination and proceed.
If the patient is on a P2Y12 inhibitor for a recent stent and now presents with chest pain, the working diagnosis may be stent thrombosis rather than a de novo ACS. Aspirin is still indicated, and the dose logic is unchanged, but the urgency of reperfusion escalates and the case should go to cardiology immediately.
FAQ
Is 150 mg enough if the patient weighs under 60 kg?
No weight-based adjustment exists for the adult aspirin loading dose in ACS. The 150 mg figure in ESC guidance is a protocol range floor, not a small-patient dose, and the antiplatelet effect at 150 mg is not reliably equivalent to 300 mg for acute loading. Use 300 mg for aspirin-naive adults regardless of weight, and reserve lower doses for patients already on maintenance therapy.
Can I give aspirin after the fibrinolytic instead of before?
Giving it after leaves the re-occlusion window unprotected during lysis. ISIS-2 showed the mortality benefit of aspirin was additive to streptokinase, and that additivity depends on the antiplatelet effect being present during and immediately after clot lysis. Give aspirin before or concurrently with the fibrinolytic infusion.
What if the patient has an aspirin allergy listed but no details?
Clarify the reaction if there is time; give the drug and monitor if there is not. True IgE-mediated aspirin anaphylaxis affects well under 1% of patients carrying the label, according to allergy literature, and most labels reflect gastrointestinal intolerance. In STEMI, an unverified allergy label that delays aspirin is a bigger risk than the reaction itself in most cases.
Does chewing actually make a difference?
Yes, and it is one of the few administration details that changes the pharmacology. Chewing a non-enteric tablet increases surface area and speeds absorption, producing near-maximal platelet inhibition within roughly 20–30 minutes instead of the 1–2 hour delay seen with enteric-coated tablets. In a time-critical pathway, that difference matters.
How does the dose compare with what ISIS-2 used?
ISIS-2 used 162.5 mg daily, not 300 mg, which is why European guidance retains a 150–300 mg range. The 300 mg figure in US and UK protocols reflects later consensus and the desire for rapid, reliable loading rather than a direct trial comparison. Both fall within the range shown to reduce mortality when combined with fibrinolysis.
Can I use intravenous aspirin if the patient is vomiting?
Intravenous aspirin is not stocked in most emergency formularies and is not standard in ACS protocols in the US or UK. If oral absorption is uncertain, use a dispersible or crushed formulation via nasogastric tube where available, document the limitation, and proceed with the fibrinolytic. Do not delay reperfusion waiting for an IV formulation that may not exist in your setting.
Is aspirin still needed if the patient is going straight to primary PCI?
Yes. Aspirin is part of the standard ACS bundle regardless of reperfusion strategy, and the 300 mg load applies in the PCI pathway as well. The surrounding antiplatelet and anticoagulant regimen differs, but aspirin remains the backbone and is typically given before or at the start of the procedure.
What is the bleeding risk of a 300 mg load in an anticoagulated patient?
It is additive but usually accepted in ACS because the coronary risk dominates. A patient on warfarin or a direct oral anticoagulant who presents with STEMI still receives aspirin in most protocols, with the decision flagged to cardiology. The bleeding risk is monitored, not used as a routine reason to withhold the drug.
This article is general educational information and not a diagnosis, treatment plan, or substitute for clinical judgment. Aspirin dosing in suspected ACS depends on individual contraindications, local protocols, and the treating clinician's assessment; consult a qualified local professional or your institution's guidance before acting. In an emergency, contact local emergency services immediately.